Intellia Therapeutics (NTLA) Stock Insights

NTLA price $13.32 +1.04 +8.47%

Ticker
NTLA
Price
$13.32
Change
+1.04 +8.47%
Market cap ?
$1.87B
P/E ?
-3.32
Forward P/E ?
12.12
Dividend yield ?
0.00%
Beta ?
1.80
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
62
Value
59
Quality
46
Growth
82

Stocklytics score rationale: value 59, quality 46, growth 82.

Financials

2016201720182019202020212022202320242025
16479000261170003043400043103000579940003305300052121000362750005787700067671000

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other…

Fair value

NTLA fair value $14.96. Price $13.32. Price is 11% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 18.97M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 1.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 140.13M. Net debt -62.13M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare NTLA

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-0.80—9.74M
2026-08-06-0.80-0.807.66M12.98M
2026-05-11-0.81-0.9215.05M13.81M
2026-02-26-0.83-0.9923.02M11.98M
2025-11-06-0.92-1.0213.78M12.17M
2025-08-07-0.99-1.0314.24M14.06M
2025-05-08-1.10-1.2616.63M11.93M
2025-02-27-1.24-1.3212.87M10.86M
2024-11-07-1.34-1.379.11M8.90M
2024-08-08-1.31-1.216.96M19.16M
2024-05-09-1.06-1.3528.93M11.50M
2024-02-22-1.46-1.471.92M12.83M
2023-11-09-1.38-1.5211.99M12.45M
2023-08-03-1.40-1.3213.59M12.08M
2023-05-04-1.17-1.4112.61M11.83M
2023-02-23-1.40-1.4013.57M11.33M
2022-11-03-1.49-1.3113.27M11.89M
2022-08-04-1.33-1.3114.03M9.42M
2022-05-05-1.96-1.1111.25M8.54M
2022-02-24-1.09-0.9112.85M8.26M
2021-11-04-0.97-0.857.20M9.49M
2021-08-05-1.01-0.616.55M5.58M
2021-05-06-0.69-0.666.45M6.15M
2021-02-25-0.69-0.576.59M5.61M
2020-11-05-0.47-0.5422.22M27.89M
2020-08-06-0.61-0.6916.26M18.40M
2020-05-07-0.63-0.3912.92M8.61M
2020-02-27-0.57-0.5410.94M10.74M
2019-10-31-0.49-0.6110.62M13.43M
2019-08-01-0.56-0.6111.12M11.91M
2019-05-02-0.49-0.5310.43M12.56M
2019-02-27-0.43-0.557.88M10.26M
2018-10-31-0.53-0.487.41M6.85M
2018-08-01-0.52-0.577.68M8.12M
2018-05-01-0.51-0.567.47M8.49M
2018-03-14-0.61-0.486.67M4.59M
2017-10-31-0.44-0.497.32M8.31M
2017-08-01-0.45-0.425.92M5.39M
2017-05-02-0.36-0.346.21M5.87M
2017-03-14-0.31-0.245.63M3.99M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-26Marantz Jing L.Buy275.06K$11.263.10M
2026-10-26Marantz Jing L.Buy199.82K——
2026-10-26Marantz Jing L.Other0——
2026-10-02Dube Michael PSell1.86K$12.4323.17K
2026-08-21LEONARD JOHN MSell2.79K$13.0036.20K
2026-08-20LEONARD JOHN MSell19.89K$12.60250.61K
2026-07-22Dulac Edward J IIISell8.11K$11.2591.25K
2026-07-02Dulac Edward J IIISell4.68K$18.0084.19K
2026-07-01Dube Michael PSell2.64K$16.7844.32K
2026-06-09Verwiel FrankBuy9.20K——
2026-06-09Verwiel FrankBuy13.30K$12.89171.44K
2026-06-09Keresty GeorgiaBuy9.20K——
2026-06-09Keresty GeorgiaBuy13.30K$12.89171.44K
2026-06-09GOODMAN JESSEBuy9.20K——
2026-06-09GOODMAN JESSEBuy13.30K$12.89171.44K
2026-06-09Goff BrianBuy9.20K——
2026-06-09Goff BrianBuy13.30K$12.89171.44K
2026-06-09Cohen Fred EBuy9.20K——
2026-06-09Cohen Fred EBuy13.30K$12.89171.44K
2026-06-09CHASE WILLIAM JBuy9.20K——
2026-06-09CHASE WILLIAM JBuy13.30K$12.89171.44K
2026-06-09Bhanji MunaBuy9.20K——
2026-06-09Bhanji MunaBuy13.30K$12.89171.44K
2026-03-02BASTA JAMESSell1.21K$13.7816.69K
2026-03-02Clark ElianaSell607$13.788.36K
2026-03-01LEONARD JOHN MBuy156.40K——
2026-03-01LEONARD JOHN MBuy225.40K$13.783.11M
2026-03-01BASTA JAMESBuy46.08K——
2026-03-01BASTA JAMESBuy65.83K$13.78907.12K
2026-03-01Lebwohl DavidBuy9.94K——
2026-03-01Lebwohl DavidBuy14.20K$13.78195.73K
2026-03-01Dulac Edward J IIIBuy61.28K——
2026-03-01Dulac Edward J IIIBuy87.54K$13.781.21M
2026-03-01Schultes Birgit CBuy39.20K——
2026-03-01Schultes Birgit CBuy56.00K$13.78771.68K
2026-03-01Clark ElianaBuy7.35K——
2026-03-01Clark ElianaBuy10.51K$13.78144.76K
2026-03-01Dube Michael PBuy17.25K——
2026-01-05LEONARD JOHN MSell34.15K$9.21314.48K
2026-01-05Schultes Birgit CSell8.51K$9.2178.36K
2026-01-05BASTA JAMESSell10.40K$9.2195.76K
2026-01-05Cohen Fred EBuy150.00K$9.351.40M
2026-01-05Lebwohl DavidSell11.90K$9.21109.63K
2026-01-05Clark ElianaSell9.52K$9.2187.63K
2026-01-05Dulac Edward J IIISell6.38K$9.2158.75K
2026-01-05Dube Michael PSell2.99K$9.2127.53K
2025-12-12LEONARD JOHN MBuy8.56K$6.8358.44K
2025-12-12LEONARD JOHN MSell8.56K$6.8358.44K
2025-12-11LEONARD JOHN MBuy49.96K$6.83341.22K
2025-12-11LEONARD JOHN MSell49.96K$9.49474.11K
2025-12-11LEONARD JOHN MSell32.83K$9.47310.92K
2025-12-11LEONARD JOHN MSell5.36K$9.5951.35K
2025-12-11LEONARD JOHN MSell49.96K$6.83341.22K
2025-10-01Schultes Birgit CSell31$17.38539
2025-10-01Dube Michael PSell1.87K$17.3832.52K
2025-08-20CHASE WILLIAM JBuy100.00K$10.031.00M
2025-07-23Dulac Edward J IIISell7.46K$14.02104.62K
2025-07-02Dube Michael PSell2.50K$9.9524.90K
2025-07-01Clark ElianaSell1.02K$9.8210.04K
2025-07-01GOODMAN JESSESell1.55K$9.2314.28K
2025-06-30GOODMAN JESSESell1.55K$9.5614.79K
2025-06-11Keresty GeorgiaBuy8.00K——
2025-06-11Keresty GeorgiaBuy11.45K$8.3795.84K
2025-06-11Verwiel FrankBuy8.00K——
2025-06-11Verwiel FrankBuy11.45K$8.3795.84K
2025-06-11GOODMAN JESSEBuy8.00K——
2025-06-11GOODMAN JESSEBuy11.45K$8.3795.84K
2025-06-11Goff BrianBuy8.00K——
2025-06-11Goff BrianBuy11.45K$8.3795.84K
2025-06-11Bhanji MunaBuy8.00K——
2025-06-11Bhanji MunaBuy11.45K$8.3795.84K
2025-06-11CHASE WILLIAM JBuy8.00K——
2025-06-11CHASE WILLIAM JBuy11.45K$8.3795.84K
2025-06-11Cohen Fred EBuy8.00K——
2025-06-11Cohen Fred EBuy11.45K$8.3795.84K
2025-04-29Bhanji MunaSell265$8.502.25K
2025-03-04Clark ElianaSell679$8.996.10K
2025-03-04BASTA JAMESSell2.57K$8.9923.12K
2025-03-01Clark ElianaBuy32.00K——
2025-03-01Clark ElianaBuy45.71K$10.09461.25K
2025-03-01LEONARD JOHN MBuy136.00K——
2025-03-01LEONARD JOHN MBuy196.00K$10.091.98M
2025-03-01Dulac Edward J IIIBuy47.20K——
2025-03-01Dulac Edward J IIIBuy67.43K$10.09680.36K
2025-03-01Dube Michael PBuy14.00K——
2025-03-01Lebwohl DavidBuy43.20K——
2025-03-01Lebwohl DavidBuy61.71K$10.09622.69K
2025-03-01Schultes Birgit CBuy37.60K——
2025-03-01Schultes Birgit CBuy53.71K$10.09541.97K
2025-03-01BASTA JAMESBuy40.00K——
2025-03-01BASTA JAMESBuy57.14K$10.09576.57K
2025-01-29Bhanji MunaSell265$9.972.64K
2025-01-13Schultes Birgit COther0——
2025-01-13Schultes Birgit COther40.00K$27.331.09M
2025-01-13Schultes Birgit COther20.00K$18.30366.00K
2025-01-13Schultes Birgit COther31.82K$32.661.04M
2025-01-13Schultes Birgit COther10.62K$14.58154.91K
2025-01-13Schultes Birgit COther3.50K$134.06469.21K
2025-01-13Schultes Birgit COther30.00K$13.40402.00K
2025-01-13Schultes Birgit COther20.60K$57.711.19M

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 354, holders +32 vs prior quarter. Ownership 108.80%.

HolderSharesChangeChange %Value
ARK INVESTMENT MANAGEMENT LLC16.88M2.37M+16.31%285.54M
BLACKROCK, INC.15.41M3.25M+26.76%260.72M
STATE STREET CORP9.23M2.31M+33.40%156.26M
VANGUARD PORTFOLIO MANAGEMENT LLC7.33M1.11M+17.82%124.06M
D. E. SHAW & CO., INC.6.44M715.15K+12.48%109.02M
VANGUARD CAPITAL MANAGEMENT LLC6.03M944.48K+18.58%102.00M
TWO SIGMA INVESTMENTS, LP5.24M529.45K+11.25%88.58M
FMR LLC4.77M2.71M+130.89%80.76M
RA CAPITAL MANAGEMENT, L.P.4.53M4.53MNew76.60M
REGENERON PHARMACEUTICALS, INC.3.70M00.00%62.65M
GEODE CAPITAL MANAGEMENT, LLC3.63M779.59K+27.34%61.45M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP3.28M1.88M+134.80%55.51M
SUMITOMO MITSUI TRUST GROUP, INC.2.90M924.47K+46.85%49.03M
AMOVA ASSET MANAGEMENT AMERICAS, INC.2.90M924.47K+46.85%49.03M
DIMENSIONAL FUND ADVISORS LP2.60M284.83K+12.29%44.04M
GOLDMAN SACHS GROUP INC2.26M636.23K+39.07%38.31M
UBS GROUP AG2.15M1.58M+278.52%36.43M
VOLORIDGE INVESTMENT MANAGEMENT, LLC2.07M454.82K+28.22%34.96M
CONTRARIUS GROUP HOLDINGS LTD1.96M43.39K+2.27%33.08M
JUPITER ASSET MANAGEMENT LTD1.85M68.44K+3.84%31.29M
MORGAN STANLEY1.73M-349.49K-16.79%29.30M
ARMISTICE CAPITAL, LLC1.50M1.16M+346.43%25.38M
RENAISSANCE TECHNOLOGIES LLC1.40M1.40MNew23.69M
NORTHERN TRUST CORP1.27M305.84K+31.65%21.52M
HRT FINANCIAL LP1.24M740.98K+147.51%21.04M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Intellia Therapeutics (NTLA) Stock Insights

NTLA$13.32+1.04 +8.47%

$1.87B

Market Cap

-3.32

P/E

12.12

Forward P/E

62

Score

Price History